{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T06:12:37Z","timestamp":1793686357333,"version":"4.5.1"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Rheumatoid arthritis (RA)-related physical limitations often hinder sustained physical activity and weight management, thereby amplifying cardiovascular risk through adverse metabolic profiles and chronic inflammation. We aimed to assess the effectiveness of semaglutide on the risk of incident major adverse cardiovascular and cerebrovascular events (MACCE) in obese adults with type 2 diabetes mellitus (T2DM) and RA in a primary-prevention setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We emulated a target trial using data from the TriNetX US database, including obese adults [aged \u226518 years; body mass index (BMI) \u226530 kg\/m2] with T2DM and comorbid RA and no prior history of stroke, heart failure (HF), acute coronary syndrome, or coronary revascularization. Using a new-user design, we compared patients initiating semaglutide with those initiating non-GLP-1 receptor agonist (GLP-1RA) second-line glucose-lowering therapies. Patients with contraindications to GLP-1RAs were excluded. Propensity-score matching (PS) (1:1) was used to balance baseline covariates. The primary outcome was incident MACCE, defined as a composite of all-cause mortality, myocardial infarction (MI), HF, or stroke. Secondary outcomes included individual MACCE components, HF hospitalization, and disease-modifying anti-rheumatic drug (DMARD) escalation, with Bonferroni correction applied for multiple comparisons. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox proportional hazards models over a follow-up of up to 2 years. Between 1 January 2014 and 1 January 2025, we identified 1200 and 2972 patients who initiated semaglutide and non-GLP-1RA therapies, respectively, within 3 months of meeting eligibility. After PS matching, 1017 semaglutide users were compared with 1017 non-GLP-1RA users (mean age 59.5 vs. 59.3 years; women 81.3% vs. 81.0%; mean BMI 38.2 vs. 38.0 kg\/m2; HbA1c, 6.8% vs. 7.0%). Semaglutide initiation was associated with a significantly lower risk of incident MACCE compared with non-GLP-1RA therapies (12.7% vs. 16.5%; HR, 0.75; 95% CI, 0.60\u20130.94; P = 0.01). This benefit was driven primarily by a lower risk of incident HF (8.9% vs. 12.5%; HR, 0.69, 95% CI, 0.53\u20130.91; P = 0\u00b7007). Semaglutide use was also associated with significantly lower DMARD escalation (16.6% vs. 21.6%; HR, 0.75; 95% CI, 0.60\u20130.90; P = 0.003). No significant differences were observed in all-cause mortality, MI, or stroke.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Among obese adults with T2DM and comorbid RA, initiation of semaglutide was associated with a reduced risk of incident MACCE, driven predominantly by a reduction in incident HF, in a primary-prevention setting. Prospective studies are needed to confirm these observations and establish causality.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvag044","type":"journal-article","created":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T11:38:23Z","timestamp":1781955503000},"page":"368-378","source":"Crossref","is-referenced-by-count":2,"title":["Semaglutide for primary prevention of major adverse cardiac and cerebrovascular events in patients with type 2 diabetes and comorbid rheumatoid arthritis: a target-trial emulation"],"prefix":"10.1093","volume":"12","author":[{"given":"Farheen","family":"Malik","sequence":"first","affiliation":[{"name":"Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine , Bronx, NY 10469 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandar","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine , Bronx, NY 10469 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9618-3267","authenticated-orcid":false,"given":"Yu","family":"Chang","sequence":"additional","affiliation":[{"name":"Section of Neurosurgery, Department of Surgery, National Cheng Kung University Hospital , Tainan 704302 ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7029-2369","authenticated-orcid":false,"given":"Ishmum","family":"Chowdhury","sequence":"additional","affiliation":[{"name":"Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine , Bronx, NY 10469 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sridhar","family":"Mangalesh","sequence":"additional","affiliation":[{"name":"Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine , Bronx, NY 10469 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Ashraf","family":"Morgan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine , Bronx, NY 10469 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezerioha","family":"Pascal","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Jacobi Medical Center\/North Central Bronx, Albert Einstein College of Medicine , Bronx, NY 10467 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishakha","family":"Modak","sequence":"additional","affiliation":[{"name":"Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine , Bronx, NY 10469 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nachum","family":"Lebovics","sequence":"additional","affiliation":[{"name":"Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine , Bronx, NY 10469 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suraj","family":"Adhikari","sequence":"additional","affiliation":[{"name":"Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine , Bronx, NY 10469 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3252-6719","authenticated-orcid":false,"given":"Pei-Lun","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine , Bronx, NY 10469 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1516-3799","authenticated-orcid":false,"given":"Wei-Cheng","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Shuang Ho Hospital, Taipei Medical University , New Taipei City 23561 ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0763-8157","authenticated-orcid":false,"given":"Kuan-Yu","family":"Chi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine , Bronx, NY 10469 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"2026081706514713900_pvag044-B1","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1016\/S2665-9913(20)30221-6","article-title":"Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout","volume":"3","author":"Hansildaar","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2026081706514713900_pvag044-B2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2024.07.016","article-title":"Exploring cardiovascular risk factors and atherosclerosis in rheumatoid arthritis","volume":"128","author":"Drosos","year":"2024","journal-title":"Eur J Intern Med"},{"key":"2026081706514713900_pvag044-B3","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41584-019-0256-0","article-title":"Cardiometabolic comorbidities in RA and PsA: lessons learned and future directions","volume":"15","author":"Ferguson","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"2026081706514713900_pvag044-B4","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s13075-016-1043-9","article-title":"Body mass index distribution in rheumatoid arthritis: a collaborative analysis from three large German rheumatoid arthritis databases","volume":"18","author":"Albrecht","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2026081706514713900_pvag044-B5","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s00296-025-05978-1","article-title":"The impact of obesity and overweight on rheumatoid arthritis patients: real-world insights from a biologic and targeted synthetic DMARDs registry","volume":"45","author":"G\u00fcler","year":"2025","journal-title":"Rheumatol Int"},{"key":"2026081706514713900_pvag044-B6","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1093\/rheumatology\/keab710","article-title":"Sarcopenic obesity in rheumatoid arthritis: prevalence and impact on physical functioning","volume":"61","author":"Baker","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2026081706514713900_pvag044-B7","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.bcp.2019.03.030","article-title":"Adipokines: linking metabolic syndrome, the immune system, and arthritic diseases","volume":"165","author":"Francisco","year":"2019","journal-title":"Biochem Pharmacol"},{"key":"2026081706514713900_pvag044-B8","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1002\/art.39136","article-title":"Weight loss, the obesity paradox, and the risk of death in rheumatoid arthritis","volume":"67","author":"Baker","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2026081706514713900_pvag044-B9","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s11926-020-00933-4","article-title":"The impact of obesity on disease activity and treatment response in rheumatoid arthritis","volume":"22","author":"Poudel","year":"2020","journal-title":"Curr Rheumatol Rep"},{"key":"2026081706514713900_pvag044-B10","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41584-025-01302-0","article-title":"Glucagon-like peptide-1 receptor agonists in arthritis: current insights and future directions","volume":"21","author":"Karacabeyli","year":"2025","journal-title":"Nat Rev Rheumatol"},{"key":"2026081706514713900_pvag044-B11","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s10067-020-04963-2","article-title":"Obesity and its role in the management of rheumatoid and psoriatic arthritis","volume":"39","author":"Moroni","year":"2020","journal-title":"Clin Rheumatol"},{"key":"2026081706514713900_pvag044-B12","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1001\/jama.2022.21383","article-title":"Target trial emulation: a framework for causal inference from observational data","volume":"328","author":"Hern\u00e1n","year":"2022","journal-title":"JAMA"},{"key":"2026081706514713900_pvag044-B13","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/ehjqcco\/qcaf104","article-title":"Global uptake of GLP-1 receptor agonists in obese, non-diabetic patients with cardiovascular disease","volume":"12","author":"Chi","year":"2025","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"2026081706514713900_pvag044-B14","doi-asserted-by":"crossref","first-page":"5912","DOI":"10.1038\/s41467-024-50199-y","article-title":"GLP-1 receptor agonists\u2019 impact on cardio-renal outcomes and mortality in T2D with acute kidney disease","volume":"15","author":"Pan","year":"2024","journal-title":"Nat Commun"},{"key":"2026081706514713900_pvag044-B15","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S1470-2045(24)00278-X","article-title":"Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study","volume":"25","author":"Wan","year":"2024","journal-title":"Lancet Oncol"},{"key":"2026081706514713900_pvag044-B16","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1001\/jama.2022.0210","article-title":"Comparison of mRNA-1273 and BNT162b2 vaccines on breakthrough SARS-CoV-2 infections, hospitalizations, and death during the delta-predominant period","volume":"327","author":"Wang","year":"2022","journal-title":"JAMA"},{"key":"2026081706514713900_pvag044-B17","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41746-021-00467-8","article-title":"A vital sign-based prediction algorithm for differentiating COVID-19 versus seasonal influenza in hospitalized patients","volume":"4","author":"Yanamala","year":"2021","journal-title":"NPJ Digit Med"},{"key":"2026081706514713900_pvag044-B18","doi-asserted-by":"crossref","first-page":"e2517541","DOI":"10.1001\/jamanetworkopen.2025.17541","article-title":"GLP-1 RA use and major adverse cardiovascular events in patients with monoclonal gammopathy of undetermined significance","volume":"8","author":"Chi","year":"2025","journal-title":"JAMA Netw Open"},{"key":"2026081706514713900_pvag044-B19","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jchf.2025.01.025","article-title":"Sodium-glucose cotransporter 2 inhibitors in tafamidis-treated transthyretin amyloid cardiomyopathy: a contemporary real-world analysis","volume":"13","author":"Chi","year":"2025","journal-title":"JACC Heart Fail"},{"key":"2026081706514713900_pvag044-B20","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","article-title":"Proportional hazards tests and diagnostics based on weighted residuals","volume":"81","author":"Grambsch","year":"1994","journal-title":"Biometrika"},{"key":"2026081706514713900_pvag044-B21","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1111\/dom.15226","article-title":"Cardiovascular prevention with glucose-lowering drugs in type 2 diabetes: an evidence-based approach to the categories of primary and secondary prevention","volume":"25","author":"Mannucci","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"2026081706514713900_pvag044-B22","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.ahj.2013.07.010","article-title":"Rheumatoid arthritis and cardiovascular disease","volume":"166","author":"Crowson","year":"2013","journal-title":"Am Heart J"},{"key":"2026081706514713900_pvag044-B23","doi-asserted-by":"crossref","first-page":"e0117952","DOI":"10.1371\/journal.pone.0117952","article-title":"The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"10","author":"Baghdadi","year":"2015","journal-title":"PLoS One"},{"key":"2026081706514713900_pvag044-B24","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1038\/s41598-020-59723-8","article-title":"The outcomes of bariatric surgery on rheumatoid arthritis disease activity: a prospective cohort study","volume":"10","author":"Xu","year":"2020","journal-title":"Sci Rep"},{"key":"2026081706514713900_pvag044-B25","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.soard.2025.10.004","article-title":"Evaluating the long-term safety and disease-modifying potential of metabolic surgery in patients with rheumatoid arthritis: a TriNetX cohort study","volume":"22","author":"Zhu","year":"2025","journal-title":"Surg Obes Relat Dis"},{"key":"2026081706514713900_pvag044-B26","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1007\/s11695-019-03995-1","article-title":"Effects of chronic corticosteroid and immunosuppressant use in patients undergoing bariatric surgery","volume":"29","author":"Hefler","year":"2019","journal-title":"Obes Surg"},{"key":"2026081706514713900_pvag044-B27","doi-asserted-by":"crossref","first-page":"e70103","DOI":"10.1002\/acr2.70103","article-title":"Effect of glucagon-like peptide 1 receptor agonists on patients with rheumatoid arthritis","volume":"7","author":"Kellner","year":"2025","journal-title":"ACR Open Rheumatol"},{"key":"2026081706514713900_pvag044-B28","doi-asserted-by":"crossref","first-page":"4479","DOI":"10.1007\/s10067-025-07709-0","article-title":"Glucagon-like peptide-1 receptor analog use is associated with reduced thromboembolic events compared with dipeptidyl peptidase-4 inhibitors in rheumatoid arthritis patients: a global retrospective cohort study","volume":"44","author":"Wang","year":"2025","journal-title":"Clin Rheumatol"},{"key":"2026081706514713900_pvag044-B29","doi-asserted-by":"crossref","first-page":"e0308533","DOI":"10.1371\/journal.pone.0308533","article-title":"Mortality and major adverse cardiovascular events after glucagon-like peptide-1 receptor agonist initiation in patients with immune-mediated inflammatory diseases and type 2 diabetes: a population-based study","volume":"19","author":"Karacabeyli","year":"2024","journal-title":"PLoS One"},{"key":"2026081706514713900_pvag044-B30","doi-asserted-by":"crossref","first-page":"e2530952","DOI":"10.1001\/jamanetworkopen.2025.30952","article-title":"GLP-1 RAs and cardiovascular and kidney outcomes by body mass index in type 2 diabetes","volume":"8","author":"Chen","year":"2025","journal-title":"JAMA Netw Open"},{"key":"2026081706514713900_pvag044-B31","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2026081706514713900_pvag044-B32","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2026081706514713900_pvag044-B33","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as compared with semaglutide for the treatment of obesity","volume":"393","author":"Aronne","year":"2025","journal-title":"N Engl J Med"},{"key":"2026081706514713900_pvag044-B34","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"2026081706514713900_pvag044-B35","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"key":"2026081706514713900_pvag044-B36","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"},{"key":"2026081706514713900_pvag044-B37","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.3899\/jrheum.141647","article-title":"Increased prevalence of diastolic heart failure in patients with rheumatoid arthritis correlates with active disease, but not with treatment type","volume":"42","author":"Schau","year":"2015","journal-title":"J Rheumatol"},{"key":"2026081706514713900_pvag044-B38","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.jacc.2025.06.055","article-title":"The adipokine hypothesis of heart failure with a preserved ejection fraction: a novel framework to explain pathogenesis and guide treatment","volume":"86","author":"Packer","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026081706514713900_pvag044-B39","volume-title":"Causal Inference: What If","author":"Hern\u00e1n","year":"2020"},{"key":"2026081706514713900_pvag044-B40","volume-title":"Causal Inference: What If","author":"Hern\u00e1n","year":"2020"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvag044\/68584264\/pvag044.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/12\/5\/368\/68584264\/pvag044.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/12\/5\/368\/68584264\/pvag044.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T10:52:09Z","timestamp":1786963929000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/12\/5\/368\/8713824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":40,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,6,23]]},"published-print":{"date-parts":[[2026,8,17]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvag044","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,6,23]]}}}